Chronic Myeloid Leukemia (CML) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034

Chronic Myeloid Leukemia (CML) Emerging Therapy

Thelansis’s “Chronic Myeloid Leukemia (CML) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Chronic Myeloid Leukemia (CML) Overview

Chronic myeloid leukemia (CML), a myeloproliferative disorder, accounts for a notable percentage of worldwide leukemia diagnoses, fundamentally characterized by the Philadelphia chromosome. This chromosomal abnormality results from a reciprocal translocation, specifically t(9;22) (q34; q11.2), which joins the BCR and ABL genes to create the oncogenic BCR/ABL fusion gene, yielding an overactive tyrosine kinase. Although CML is not inherited, the precise environmental or genetic risk factors that cause it are still unknown. The disease naturally evolves through three distinct stages: the chronic phase (CML-CP), the accelerated phase (CML-AP), and the blast phase (CML-BP). Most patients are diagnosed during the CML-CP, which can often be discovered incidentally when asymptomatic, or present with non-specific signs such as fatigue, unexplained weight loss, night sweats, anemia, or an enlarged spleen (splenomegaly). Treatment strategies for chronic myeloid leukemia vary based on disease stage. In the asymptomatic chronic phase, initial therapy usually involves tyrosine kinase inhibitors (such as imatinib, nilotinib, dasatinib, bosutinib, and ponatinib), demonstrating high efficacy, although not curative. These inhibitors may also be employed in the accelerated or blast phases.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Chronic Myeloid Leukemia (CML) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034